JPMorgan Chase & Co. has filed a major holdings notification disclosing that its combined voting rights position in Bodycote plc (BOY), the UK-listed heat treatment and thermal processing specialist, reached 7.933484% on 9 November 2026, crossing a regulatory reporting threshold. The notification was submitted to Bodycote on 11 November 2026 and completed in London. The disclosure covers both direct share holdings and a substantial portfolio of cash-settled equity swaps held through J.P. Morgan Securities PLC, and represents a change from JPMorgan's previously notified position of 7.952435%.

Key Points

  • Bodycote plc (BOY), UK-listed thermal processing and heat treatment group
  • JPMorgan Chase & Co. notified a total combined voting rights position of 7.933484% as at 9 November 2026
  • Direct share voting rights stand at 1.474330%, representing 2,509,132 shares; financial instruments account for a further 6.459154%
  • Investors may watch whether JPMorgan's position changes further, given the previous notification stood marginally higher at 7.952435%

JPMorgan's Combined Position in Bodycote Reaches 13.5 Million Voting Rights

According to the TR-1 form filed under UK Disclosure and Transparency Rules, JPMorgan Chase & Co. holds a total of 13,501,836 voting rights in Bodycote plc across all instruments. Of these, 2,509,132 are direct voting rights attached to shares, equating to 1.474330% of total voting rights. The remaining 6.459154% derives entirely from cash-settled equity swaps held through J.P. Morgan Securities PLC, a wholly-owned subsidiary within the JPMorgan group structure. The notification states that J.P. Morgan SE and J.P. Morgan Markets Limited are also part of the controlling chain, though their individual positions do not independently meet the notifiable threshold.

Eighteen Cash-Settled Equity Swaps Underpin JPMorgan's Bodycote Exposure

The financial instruments disclosed under Section 8B2 of the notification comprise eighteen separate cash-settled equity swap positions, all settled in cash rather than through physical delivery of shares. Expiry dates on these instruments range from 30 November 2026 through to 15 December 2027, with the largest individual position being a swap over 2,600,756 voting rights expiring 29 July 2027, equivalent to 1.528167% of voting rights. Because these are cash-settled instruments, they do not confer direct ownership or voting control over the underlying Bodycote shares, a distinction material to assessing the nature of JPMorgan's economic exposure.

Bodycote's Position as a FTSE-Listed Thermal Processing Group Gives Context to the Filing

Bodycote plc is a specialist provider of heat treatment, hot isostatic pressing, and thermal processing services, operating facilities across Europe and North America. The company's services are integral to aerospace, automotive, and industrial manufacturing supply chains, providing essential material performance enhancement. Major institutional holders routinely adjust positions in companies of Bodycote's profile as part of portfolio management, derivatives trading, and hedging strategies. The TR-1 filing reflects standard regulatory transparency requirements under the UK's Disclosure and Transparency Rules rather than any publicly stated strategic intent on JPMorgan's part.

Shift From Previous JPMorgan Notification Reflects Rebalancing of Share and Swap Exposure

Comparing the current notification with the previous filing reveals a notable internal rebalancing. Voting rights attached to direct shares rose from 0.545526% to 1.474330%, while voting rights through financial instruments fell from 7.406909% to 6.459154%. The overall combined total edged marginally lower, from 7.952435% to 7.933484%. The announcement does not disclose the timing or rationale for the previous notification, nor does it provide any forward-looking guidance on JPMorgan's intended holding strategy in Bodycote plc.